Literature DB >> 23512980

The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.

Zachary R Hartman1, Michael D Schaller, Yehenew M Agazie.   

Abstract

The Src homology phosphotyrosyl phosphatase 2 (SHP2) is a positive effector of receptor tyrosine kinases (RTK) signaling. Furthermore, SHP2 is known to promote cell migration and invasiveness, key steps in cancer metastasis. To date, however, the mechanism by which SHP2 regulates cell movement is not fully understood. In the current report, a new role for SHP2 in regulating cell migration has been suggested. We show that SHP2 mediates lamellipodia persistence and cell polarity to promote directional cell migration in the MDA-MB231 and the MDA-MB468 basal-like and triple-negative breast cancer cell lines. We further show that SHP2 modulates the activity of focal adhesion kinase (FAK) by dephosphorylating pTyr397, the autophosphorylation site that primes FAK function. Because hyperactivation of FAK is known to counter the maturation of nascent focal complexes to focal adhesions, we propose that one of the mechanisms by which SHP2 promotes lamellipodia persistence is by downregulating FAK activity through dephosphorylation of pTyr397. The finding that inhibition of FAK activity partially restores EGF-induced lamellipodia persistence and cell migration in SHP2-silenced cells supports our proposition that SHP2 promotes growth factor-induced cell movement by acting, at least in part, on FAK. However, the effect of SHP2 inhibition in nonstimulated cells seems FAK independent as there was no significant difference between the control and the SHP2-silenced cells in pY397-FAK levels. Also, FAK inhibition did not rescue Golgi orientation defects in SHP2-silenced cells, suggesting that SHP2 acts through other mechanisms to promote cell polarity. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23512980      PMCID: PMC3686999          DOI: 10.1158/1541-7786.MCR-12-0578

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  46 in total

1.  Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Authors:  S Pintens; P Neven; M Drijkoningen; V Van Belle; P Moerman; M-R Christiaens; A Smeets; H Wildiers; I Vanden Bempt
Journal:  J Clin Pathol       Date:  2009-07       Impact factor: 3.411

2.  The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.

Authors:  Xiangdong Zhou; Yehenew M Agazie
Journal:  Cell Signal       Date:  2011-09-03       Impact factor: 4.315

3.  Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.

Authors:  V Martin; F Botta; E Zanellato; F Molinari; S Crippa; L Mazzucchelli; M Frattini
Journal:  Histol Histopathol       Date:  2012-06       Impact factor: 2.303

Review 4.  The tyrosine phosphatase Shp2 in development and cancer.

Authors:  Katja S Grossmann; Marta Rosário; Carmen Birchmeier; Walter Birchmeier
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

5.  Effects of brefeldin A-inhibited guanine nucleotide-exchange (BIG) 1 and KANK1 proteins on cell polarity and directed migration during wound healing.

Authors:  Chun-Chun Li; Jean-Cheng Kuo; Clare M Waterman; Ryoiti Kiyama; Joel Moss; Martha Vaughan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

6.  Cortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence.

Authors:  Laura C Kelley; Karen E Hayes; Amanda Gatesman Ammer; Karen H Martin; Scott A Weed
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

7.  Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells.

Authors:  Jeremy Bregeon; Gervaise Loirand; Pierre Pacaud; Malvyne Rolli-Derkinderen
Journal:  Am J Physiol Cell Physiol       Date:  2009-08-19       Impact factor: 4.249

8.  Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.

Authors:  X-D Zhou; Y M Agazie
Journal:  Cell Death Differ       Date:  2008-04-18       Impact factor: 15.828

9.  Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.

Authors:  Xiangdong Zhou; Yehenew M Agazie
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

10.  Regulation of RhoA-dependent ROCKII activation by Shp2.

Authors:  Hsiao-Hui Lee; Zee-Fen Chang
Journal:  J Cell Biol       Date:  2008-06-16       Impact factor: 10.539

View more
  35 in total

1.  T cell activation is reduced by the catalytically inactive form of protein tyrosine phosphatase SHP-2.

Authors:  Baoxia Dong; Yubo Gao; Xuan Zheng; Guangxun Gao; Hongtao Gu; Xiequn Chen; Jinyi Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling.

Authors:  Anthony Ambesi; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2014-06-30       Impact factor: 5.285

3.  A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).

Authors:  Zachary Hartman; Werner J Geldenhuys; Yehenew M Agazie
Journal:  J Biol Chem       Date:  2020-02-04       Impact factor: 5.157

4.  In Vivo CRISPR Screen Identifies TgWIP as a Toxoplasma Modulator of Dendritic Cell Migration.

Authors:  Lamba Omar Sangaré; Einar B Ólafsson; Yifan Wang; Ninghan Yang; Lindsay Julien; Ana Camejo; Patricia Pesavento; Saima M Sidik; Sebastian Lourido; Antonio Barragan; Jeroen P J Saeij
Journal:  Cell Host Microbe       Date:  2019-10-09       Impact factor: 21.023

5.  Cytotoxic activity of Shp2 inhibitor fumosorinone in human cancer cells.

Authors:  Chuan Chen; Tongdan Xue; Peng Fan; Linlin Meng; Jingjing Wei; Duqiang Luo
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

6.  Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma.

Authors:  Zhong-Qian Hu; Rui Ma; Chi-Min Zhang; Jia Li; Ling Li; Zhong-Ting Hu; Q I Gao; Wei-Min Li
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

7.  Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.

Authors:  Jiawei Zheng; Shanshan Huang; Yufang Huang; Li Song; Yin Yin; Wencui Kong; Xiong Chen; Xuenong Ouyang
Journal:  Tumour Biol       Date:  2015-12-23

8.  The Protein Tyrosine Phosphatase Shp2 Regulates Oligodendrocyte Differentiation and Early Myelination and Contributes to Timely Remyelination.

Authors:  Jared T Ahrendsen; Danielle E Harlow; Lisbet T Finseth; Jennifer N Bourne; Sean P Hickey; Elizabeth A Gould; Cecilia M Culp; Wendy B Macklin
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

9.  SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function.

Authors:  Havovi Chichger; Julie Braza; Huetran Duong; Elizabeth O Harrington
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

10.  Human phosphatase CDC14A is recruited to the cell leading edge to regulate cell migration and adhesion.

Authors:  Nan-Peng Chen; Borhan Uddin; Renate Voit; Elmar Schiebel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.